Cargando…

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic

BACKGROUND: Carbapenem-resistant Acinetobacter baumannii infections are difficult to treat and are a significant public health threat due to intrinsic/acquired resistance and limited treatment options. METHODS: A retrospective, observational cohort study in patients receiving cefiderocol via Shionog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannella, Maddalena, Verardi, Stefano, Karas, Andreas, Abdel Hadi, Hasania, Dupont, Hervé, Soriano, Alex, Santerre Henriksen, Anne, Cooper, Andrew, Falcone, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368198/ https://www.ncbi.nlm.nih.gov/pubmed/37496600 http://dx.doi.org/10.1093/ofid/ofad329

Ejemplares similares

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance
por: Longshaw, Christopher M, et al.
Publicado: (2022)

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study
por: Pascale, Renato, et al.
Publicado: (2021)

Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection
por: Mabayoje, Diana A, et al.
Publicado: (2021)

Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
por: Falcone, Marco
Publicado: (2021)

2759. Cefiderocol vs Best Available Therapy for the Treatment of Carbapenem- Resistant Acinetobacter baumannii
por: Daisey, Gabrielle N, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates
por: Seifert, Harald, et al.
Publicado: (2023)

2134. Impact of ADC ß-lactamase amino acid variation on cefiderocol (FDC) susceptibility in carbapenem-resistant Acinetobacter baumannii (CRAb) strains
por: Iovleva, Alina, et al.
Publicado: (2023)

Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia
por: Son, Hyo-Ju, et al.
Publicado: (2020)

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
por: Kaye, Keith S., et al.
Publicado: (2023)

Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa
por: Cai, Bin, et al.
Publicado: (2017)

In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
por: Quirino, Angela, et al.
Publicado: (2023)

Containment of a carbapenem-resistant Acinetobacter baumannii complex outbreak in a COVID-19 intensive care unit
por: Eckardt, Paula, et al.
Publicado: (2022)

US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to Enterobacterales
por: Lodise, Thomas P, et al.
Publicado: (2021)

Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability
por: Stracquadanio, Stefano, et al.
Publicado: (2022)

Increased Capsule Thickness and Hypermotility Are Traits of Carbapenem-Resistant Acinetobacter baumannii ST3 Strains Causing Fulminant Infection
por: Rakovitsky, Nadya, et al.
Publicado: (2021)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
por: Sajib, Monirul I., et al.
Publicado: (2023)

Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021)

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials
por: Longshaw, Christopher, et al.
Publicado: (2022)

Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant Acinetobacter baumannii
por: He, Yukun, et al.
Publicado: (2022)

Acinetobacter baumannii response to cefiderocol challenge in human urine
por: Nishimura, Brent, et al.
Publicado: (2022)

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii
por: Raro, Otávio Hallal Ferreira, et al.
Publicado: (2023)

2752. Outcomes of Patients with Stenotrophomonas maltophilia infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023)

Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options
por: Bartal, Carmi, et al.
Publicado: (2022)

Induced Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii (CRAB) via Exposure to Human Pleural Fluid (HPF) and Its Impact on Cefiderocol Susceptibility
por: Mezcord, Vyanka, et al.
Publicado: (2023)

Mechanism of action of cefiderocol
por: Soriano, Alex, et al.
Publicado: (2022)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
por: Bonomo, Robert A
Publicado: (2019)

Treatment of Piperacillin-Tazobactam–Nonsusceptible/Ceftriaxone-Susceptible Infections With Carbapenem Versus Carbapenem-Sparing Antimicrobials
por: Cao, John, et al.
Publicado: (2023)

Performance of the Disc Diffusion Method, MTS Gradient Tests and Two Commercially Available Microdilution Tests for the Determination of Cefiderocol Susceptibility in Acinetobacter spp.
por: Jeannot, Katy, et al.
Publicado: (2023)

2750. Pseudomonas aeruginosa infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023)

Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19
por: Russo, A., et al.
Publicado: (2023)

Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study
por: Bavaro, Davide Fiore, et al.
Publicado: (2023)

P43 In vitro activity of cefiderocol and comparators against Gram-negative pathogens: ARTEMIS study in the UK
por: Wareham, D., et al.
Publicado: (2022)

Erratum to: Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction; Antibiotic resistance during and beyond COVID-19; Education: An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice; Education: A compassionate use of cefiderocol to treat osteomyelitis caused by an XDR Pseudomonas aeruginosa; Compassionate use of cefiderocol for carbapenem-resistant Acinetobacter baumannii prosthetic joint infection; Education: An overview from the author of ‘Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients’
Publicado: (2021)

Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
por: Shields, Ryan K, et al.
Publicado: (2023)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k049jn5an1h62j8ne1asgf7mtj